Menopause

Data presented at the 2024 Annual Meeting of The Menopause Society highlighted greater reductions in hot flash severity among women receiving clinical hypnosis compared to those receiving cognitive behavioral therapy.

In a recent study, reduced aging discrepancies were observed in postmenopausal women reporting hormone therapy use vs nonusers.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Astellas Pharma has announced the first dose administration of fezolinetant to manage moderate to severe vasomotor symptoms in breast cancer patients using adjuvant endocrine therapy.

A significant connection has been identified between severe menopause symptoms and cognitive impairment in postmenopausal women, according to findings from a study published in Menopause, the journal of The Menopause Society.

A recent study found that women with a shorter reproductive lifespan had increased odds of multimorbidity compared to those with a longer reproductive lifespan, indicating a need to assess reproductive factors to determine high-risk patients.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Bayer has submitted a New Drug Application for elinzanetant, following positive results from the OASIS studies, showing significant safety and efficacy in treating moderate-to-severe vasomotor symptoms in menopausal women.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A new study recently published in Menopause, the journal of The Menopause Society, suggests a significant link between chronic kidney disease (CKD) and tooth loss, particularly in postmenopausal women.

Risa Kagan, MD, discusses the efficacy of fezolinetant in reducing the frequency and severity of vasomotor symptoms in menopausal women, offering an alternative to traditional hormonal therapies.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Though studies on the prevalence of depression during menopause vary, for those experiencing the symptoms, quality of life can be severely compromised.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

New research reveals that acute increases in physical activity and ambient temperature can elevate the risk of both objective and subjective hot flashes in postmenopausal women.

Review some of the top stories from Contemporary OB/GYN's coverage of ACOG 2024, and catch up on anything you may have missed.

Dive into the research presented by Rhonda R. Voskuhl at ACOG 2024, shedding light on the potential of estrogen receptor beta as a target to mitigate cognitive decline in postmenopausal women.

At ACOG 2024, Monica M. Christmas, MD, FACOG, and Stephanie Faubion, MD, emphasize the importance of combating disinformation in menopause care and provide clinicians with evidence-based strategies to manage symptoms effectively.

Phase 3 data presented by JoAnn Pinkerton, MD, reveals that elinzanetant significantly improves hot flash frequency, sleep, and overall menopause quality of life, offering a promising alternative to estrogen therapy.

Michelle Jacobson, MD, MHSc, FRCSC, shares critical perspectives on managing vasomotor symptoms in breast cancer patients at the recent ACOG Annual Clinical & Scientific Meeting, emphasizing the importance of tailored approaches amidst evolving treatment options and patient risks.

A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A recent study revealed an association between premature menopause and increased risks of musculoskeletal pain and sarcopenia, emphasizing the potential benefits of hormone therapy in mitigating long-term effects.

A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Learn how to prepare for your menopause healthcare visit effectively and make the most out of your time with health care professionals, as advised by experts selected by The Menopause Society.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Bayer's OASIS 3 trial affirmsed the safety and efficacy of elinzanetant in reducing moderate to severe vasomotor symptoms, bolstering confidence in its potential as a non-hormonal solution for menopause-related issues.

Delve into the connection between nighttime vasomotor symptoms and Alzheimer's disease risk in women, shedding light on potential modifiable factors impacting cognitive health.